NCT02041481View on ClinicalTrials.gov

MEK Inhibitor MEK162 in Combination With Leucovorin Calcium, Fluorouracil, and Oxaliplatin in Treating Patients With Advanced Metastatic Colorectal Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

26

Participants

Timeline

Start Date

June 30, 2014

Primary Completion Date

January 19, 2018

Study Completion Date

January 19, 2018

Conditions
Recurrent Colon CancerRecurrent Rectal CancerStage IVA Colon CancerStage IVA Rectal CancerStage IVB Colon CancerStage IVB Rectal Cancer
Interventions
DRUG

MEK inhibitor MEK162

Given PO

DRUG

leucovorin calcium

Given IV

DRUG

fluorouracil

Given IV

DRUG

oxaliplatin

Given IV

OTHER

pharmacological study

Correlative studies

OTHER

Laboratory Biomarker Analysis

Correlative Studies

Trial Locations (1)

91010

City of Hope Medical Center, Duarte

Sponsors

Collaborators (1)

Array BioPharma
All Listed Sponsors
collaborator

National Cancer Institute (NCI)

NIH

collaborator

Array BioPharma

INDUSTRY

lead

City of Hope Medical Center

OTHER